COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial

By sjmartinez • November 28, 2023

Habtehyimer F, Zhu X, Redd AD, Gebo KA, Abraham AG, Patel EU, Laeyendecker O, Gniadek TJ, Fernandez RE, Baker OR, Ram M, Cachay ER, Currier JS, Fukuta Y, Gerber JM, Heath SL, Meisenberg B, Huaman MA, Levine AC, Shenoy A, Anjan S, Blair JE, Cruser D, Forthal DN, Hammitt LL, Kassaye S, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Abinante M, Oei KS, Cluzet V, Cordisco ME, Greenblatt B, Rausch W, Shade D, Gawad AL, Klein SL, Pekosz A, Shoham S, Casadevall A, Bloch EM, Hanley D, Tobian AAR, Sullivan DJ. COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial. Microbiol Spectr. 2023 Nov 27:e0328623. doi: 10.1128/spectrum.03286-23. Epub ahead of print. PMID: 38009954.

Tags: chemokines, convalescent plasma, covid-19, COVID-19 serotherapy, Cytokines, Infectious Diseases, Publications, randomized trial, SARS-CoV-2

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

Gebremariam T, Gu Y, Patterson H, Youssef E, Alkhazraji S, Elsayed T, Wiederhold NP, Ibrahim AS. Efficacy assessments of SF001, a next-generation polyene antifungal, in[...]

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

Dao KT, D'Assumpcao C, Sharma R, Singh C, Kuran R, Heidari A. Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Cureus. 2025 Feb 24;17(2):e79588.[...]

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes[...]